JN Biosciences LLC

Bridging Science to Life

JN Biosciences LLC
320 Logue Avenue
Mountain View, CA 94043

  • Home
  • ManagementClick to open the Management menu
    • Naoya Tsurushita, Ph.D.
    • J Yun Tso, Ph.D.
  • Technology
  • PipelineClick to open the Pipeline menu
    • CD122
    • Death Receptors
    • Costimulatory Molecules
    • Checkpoint Molecules
    • Bispecific antibodies
  • Humanization
  • Partnering
  • NewsClick to open the News menu
    • 2022
    • 2021
    • 2019 - 2020
    • 2018
    • 2017
    • 2016
    • 2012 - 2015
  • Contact

Anti-Death Receptor Antibodies

HuYON007 MultYbody™ is a humanized anti-death receptor 4 (DR4) IgG1 antibody which has been converted to an agonist using JN Biosciences' proprietary MultYmab™ antibody engineering technology.  HuYON007 MultYbody™ potently induces apoptosis of DR4-expressing tumor cell lines such as Burkitt's lymphoma Ramos, multiple myeloma RPMI-8226, colon carcinoma COLO 205 and pancreatic carcinoma MIA PaCa-2.  In a systemic xenograft model with each of Ramos and RPMI-8226 cells, HuYON007 was significantly more efficacious than non-engineered HuYON007 IgG1 for survival of the mice.  HuYON007 MultYbody™ is being developed for treatment of cancer.  For additional information of HuYON007 MultYbody™, a non-confidential brochure is available here.

HuGOH729S MultYbody™ is a humanized anti-death receptor 5 (DR5) IgG1 antibody which has been converted to an agonist using JN Biosciences' proprietary MultYmab™ antibody engineering technology.  HuGOH729S MultYbody™ potently induces apoptosis of DR5-expressing tumor cell lines such as acute T cell leukemia Jurkat, colon carcinoma COLO 205 and ovarian carcinoma OVCAR-3.  The therapeutic efficacy of HuGOH729S MultYbody™ is currently being examined.


Copyright 2022 JN Biosciences. All rights reserved.

 

JN Biosciences LLC
320 Logue Avenue
Mountain View, CA 94043